Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.
$15.02B net income for the year ended March 31, 2026. These are reported results, not a forecast or a stock recommendation.
Latest-filed standard financial facts · USD
Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.
Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.
| Reported period | Reported value | Filed | Source |
|---|---|---|---|
| April 1, 2025 – March 31, 2026 | $148,401,000,000 | May 20, 2026 | 20-F ↗ |
| April 1, 2024 – March 31, 2025 | $137,300,000,000 | June 26, 2025 | 20-F ↗ |
| April 1, 2023 – March 31, 2024 | $130,350,000,000 | May 23, 2024 | 20-F ↗ |
| April 1, 2022 – March 31, 2023 | $126,491,000,000 | July 21, 2023 | 20-F ↗ |
| April 1, 2021 – March 31, 2022 | $134,567,000,000 | July 26, 2022 | 20-F ↗ |
| April 1, 2020 – March 31, 2021 | $109,480,000,000 | July 27, 2021 | 20-F ↗ |
| April 1, 2019 – March 31, 2020 | $71,985,000,000 | July 9, 2020 | 20-F ↗ |
| April 1, 2018 – March 31, 2019 | $56,152,000,000 | June 5, 2019 | 20-F ↗ |
One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.
Concept: us-gaap:Revenues · Retrieved October 8, 2026
Response SHA-256: 66f5eb1c036515728219ec6983e6d74be34201eb5abbeb4d5120b0aa5dd5ff9f
Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.